Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Feb;114(3):656–661. doi: 10.1111/j.1476-5381.1995.tb17189.x

Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.

E Udvary 1, J G Papp 1, A Végh 1
PMCID: PMC1510011  PMID: 7735692

Abstract

1. The haemodynamic effects of a novel cardiotonic drug, levosimendan, which has both calcium-sensitizing and phosphodiesterase III (PDE III) inhibitory properties, were studied in conscious dogs in which heart failure had been induced by prolonged cardiac pacing in the presence of aortic constriction. These effects were compared with those in sham-operated dogs with essentially normal cardiac function. 2. Eighteen mongrel dogs were instrumented for the measurement of left ventricular pressure (LVSP, LVEDP) and contractile function (dP/dt; dP/dt/P). In twelve dogs a balloon catheter, positioned in the thoracic aorta, was inflated producing an approximate 60% reduction in effective aortic diameter. Twenty min later rapid ventricular pacing (240 beats mean-1) was commenced and maintained for 48 h by means of a bipolar pacing electrode introduced into the right ventricle. This electrode served also for recording changes in the endocardial electrogram in the absence of pacing. Six of these dogs were used to evaluate the haemodynamic changes of pacing-induced heart failure; a further six of these dogs the haemodynamic changes elicited by levosimendan under these conditions. Six sham-operated dogs (group 2) served as controls. 3. In six dogs (group 1) the haemodynamic alterations were assessed after the development of heart failure. In the presence of aortic constriction, 48 h continuous rapid cardiac pacing resulted in a marked deterioration in left ventricular function which remained stable for at least 48 h after cessation of pacing. Thus, there was a marked reduction in LVSP (15%), +dP/dtmax (35%), -dP/dtmax (36%) and also in dP/dt/P (29%), whereas LVEDP was increased considerably (from 6.4 +/- 1.4 to 20.0 +/- 2.2 mmHg).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
656

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe Y., Kitada Y., Narimatsu A. Effect of MCI-154, a cardiotonic agent, on regional contractile function and myocardial oxygen consumption in the presence and absence of coronary artery stenosis in dogs. J Pharmacol Exp Ther. 1993 May;265(2):819–825. [PubMed] [Google Scholar]
  2. Armstrong P. W., Stopps T. P., Ford S. E., de Bold A. J. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 1986 Nov;74(5):1075–1084. doi: 10.1161/01.cir.74.5.1075. [DOI] [PubMed] [Google Scholar]
  3. Beier N., Harting J., Jonas R., Klockow M., Lues I., Haeusler G. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer". J Cardiovasc Pharmacol. 1991 Jul;18(1):17–27. doi: 10.1097/00005344-199107000-00004. [DOI] [PubMed] [Google Scholar]
  4. Lues I., Beier N., Jonas R., Klockow M., Haeusler G. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol. 1993 Jun;21(6):883–892. doi: 10.1097/00005344-199306000-00006. [DOI] [PubMed] [Google Scholar]
  5. Marban E., Kitakaze M., Koretsune Y., Yue D. T., Chacko V. P., Pike M. M. Quantification of [Ca2+]i in perfused hearts. Critical evaluation of the 5F-BAPTA and nuclear magnetic resonance method as applied to the study of ischemia and reperfusion. Circ Res. 1990 May;66(5):1255–1267. doi: 10.1161/01.res.66.5.1255. [DOI] [PubMed] [Google Scholar]
  6. Moe G. W., Angus C., Howard R. J., Parker T. G., Armstrong P. W. Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res. 1992 Apr;26(4):362–366. doi: 10.1093/cvr/26.4.362. [DOI] [PubMed] [Google Scholar]
  7. Nuttall A., Smith H. J., Loveday B. E. A clinically relevant model of heart failure: effects of ticlopidine. Cardiovasc Res. 1985 Apr;19(4):187–192. doi: 10.1093/cvr/19.4.187. [DOI] [PubMed] [Google Scholar]
  8. Rüegg J. C., Pfitzer G., Eubler D., Zeugner C. Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methy l-3(2H )- pyridazinone. Arzneimittelforschung. 1984;34(12):1736–1738. [PubMed] [Google Scholar]
  9. Végh A., Szekeres L., Udvary E. Effect of the blood supply to the normal noninfarcted myocardium on the incidence and severity of early post-occlusion arrhythmias in dogs. Basic Res Cardiol. 1987 Mar-Apr;82(2):159–171. doi: 10.1007/BF01907063. [DOI] [PubMed] [Google Scholar]
  10. Wilson J. R., Douglas P., Hickey W. F., Lanoce V., Ferraro N., Muhammad A., Reichek N. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation. 1987 Apr;75(4):857–867. doi: 10.1161/01.cir.75.4.857. [DOI] [PubMed] [Google Scholar]
  11. Wolk M. J., Keefe J. F., Bing O. H., Finkelstein L. J., Levine H. J. Estimation of Vmax in auxotonic systoles from the rate of relative increase of isovolumic pressure: (dP-dt)kP. J Clin Invest. 1971 Jun;50(6):1276–1285. doi: 10.1172/JCI106606. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES